Effects of Omalizumab on Serum Levels of Substance P, Calcitonin Gene-Related Peptide, Neuropeptide Y, and Interleukin-31 in Patients with Chronic Spontaneous Urticaria

Table 4

Change in serum substance P, calcitonin gene-related peptide, neuropeptide Y, and interleukin-31.

	Baseline	3rd month	6th month	p Value
	Median (Q1–Q3)	Median (Q1–Q3)	Median (Q1–Q3)
SP^†	19.51 (14.51–26.89)^b	21.04 (17.24–26.86)^ab	22.78 (17.95–37.35)^a
CGRP^‡	45.29 (31.99–73.08)^b	54.25 (41.46–74.84)^b	72.81 (45.54–104.37)^a
NPY^§	185.3 (135.06–270.26)	171.58 (142.94–245.89)	176.11 (135.55–241.35)	0.872
IL-31^¶	65.3 (46.39–89.14)^a	60.97 (36.51–80.13)^b	59.42 (39.61–78.9)^b

Note: Friedman test.^†Substance P, ^‡Calcitonin gene-related peptide, ^§Neuropeptide Y, ^¶Interleukin-31. ^a,bDifferent letters indicate which group the difference originates from (Dunn’s test).